An early analysis from the ongoing RESTORE trial suggests semaglutide may improve fertility-related outcomes in females with polyendocrine metabolic ovarian syndrome (PMOS), formerly known as PCOS. A review also suggests that GLP-1 drugs may support male reproductive health in those with obesity by improving testosterone levels, reproductive hormones, and sperm quality while also improving metabolic health. The findings support the idea that tre…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.